BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...

Early detection and prevention of cancer can save lives, but current tools often fall short because of suboptimal accuracy and limited accessibility. The Fred Hutch Cancer Center aims to change that ...

Metastatic breast cancer subtypes and biomarkers are crucial for guiding treatment decisions and managing disease progression. ER-positive, HER2-negative breast cancer treatment often begins with ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including ...

Despite the clinical utility of biomarker testing in patients with prostate cancer, the tests are infrequently ordered, preventing optimized care. Despite guideline recommendations and the efficacy of ...

When Ginny Mason was diagnosed with inflammatory breast cancer in 1994, she never once heard the word “biomarker.” “Back then, all you got was ER and PR [the estrogen receptor and progesterone ...

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing ...

Huntsman Cancer Institute at the University of Utah (the U), in collaboration with the John and Marcia Price College of Engineering, the Department of Radiation Oncology, and the Division of ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...